A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes

NCT01059812 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

424

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec/insulin aspart
DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S